Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed, has come back, or has spread to other parts of the body — confirmed by a tissue biopsy.
• People whose liver cancer tumors test positive for a protein called GPC3, measured by a laboratory test on tumor tissue (the required level depends on which part of the trial a person is joining — confirm with trial site).
• People who have already received at least one standard drug treatment for their liver cancer and whose cancer has continued to grow, or who were unable to tolerate that treatment.
• People who, in the treating doctor's opinion, are expected to live for at least 4 months.
• People who are reasonably active and able to care for themselves, rated 0 or 1 on a standard medical activity scale (meaning fully active or restricted in strenuous activity only).
• People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines.
• People whose liver is functioning at a certain minimum level, as measured by a scoring system called Child-Pugh (score of A6 or better — confirm with trial site).
• People whose heart, kidneys, liver, and other organs are functioning adequately.

Who may not be able to join:

• People with a pre-existing illness (for example, severe heart failure) that would make it difficult to participate fully in the study.
• People with an active, uncontrolled bacterial, fungal, or viral infection. People living with HIV, hepatitis B, or hepatitis C may still be considered if their infection is being treated and their virus levels are under control.
• People who have had another type of cancer within the past 5 years — with exceptions for certain low-risk skin cancers, early-stage cervical cancer, or other cancers considered unlikely to return.
• People with cancer that has spread to the brain or nervous system that has not been adequately treated. People with previously treated brain metastases, with no remaining neurological problems and no need for steroids or anti-seizure medication, may still be considered.
• People who are pregnant or breastfeeding.
• People who have received treatments directed at the liver tumor (such as radiation, ablation, or embolisation) or have had liver surgery within 14 days before joining the study.
• People who are currently participating in another clinical trial or receiving another experimental treatment at the same time.
• People with an active autoimmune disease that requires ongoing immune-suppressing medication.
• People with a specific type of blood clot in the main vein supplying the liver (called Vp4 portal vein tumour thrombus), or cancer growing into the large vein near the liver (inferior vena cava) — unless that condition was treated and has been stable on imaging for at least 6 months.
• People with fluid build-up in the abdomen (ascites) that requires active management such as drainage procedures or increasing diuretic doses. People who are stable on a steady dose of diuretics with no symptoms may still be considered.
• People who have had a significant gastrointestinal bleeding episode (Grade 3 or higher on a standard medical scale) within the 6 months before screening.
• People with certain blood clotting abnormalities, unless the abnormality is due to a blood-thinning medication that the treating doctor considers safe to manage during the study.
• People who have had an organ transplant at any time in the past.
• People whose liver cancer takes up more than half of the total liver volume.
• People who have had a severe allergic reaction (including anaphylaxis) to any component of the study drug (ECT204), mouse-derived antibodies, or iron-dextran.
• People who have previously received a gene therapy treatment such as CAR-T cell therapy. People who have previously received oncolytic virus therapy may still be considered.
• People for whom the process of collecting white blood cells (leukapheresis) or receiving the preparation medications before treatment would be medically unsuitable.

Important: Always verify eligibility with the trial site directly before applying.